Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2007 3
2009 1
2010 1
2011 1
2012 1
2013 2
2014 1
2015 3
2016 2
2017 3
2018 3
2019 3
2020 3
2021 6
2022 7
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Extensive Stage Lung Small Cell Carcinoma"
Page 1
Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J, Wang J, Xu H. Chen J, et al. Medicine (Baltimore). 2021 Apr 16;100(15):e25180. doi: 10.1097/MD.0000000000025180. Medicine (Baltimore). 2021. PMID: 33847617 Free PMC article.
BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) including atezolizumab, durvalumab, pembrolizumab, and nivolumab have reported their efficacy and safety profile in patients with extensive-stage small cell lung cancer (ES-SCLC). …
BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) including atezolizumab, durvalumab, pembrolizumab, and nivolumab have repor …
Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis.
Sathiyapalan A, Febbraro M, Pond GR, Ellis PM. Sathiyapalan A, et al. Curr Oncol. 2022 Nov 22;29(12):9046-9065. doi: 10.3390/curroncol29120709. Curr Oncol. 2022. PMID: 36547123 Free PMC article. Review.
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with early metastatic potential. ...
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with early metastatic potential. ...
Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis.
Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Palma DA, et al. Clin Lung Cancer. 2016 Jul;17(4):239-44. doi: 10.1016/j.cllc.2015.09.007. Epub 2015 Oct 1. Clin Lung Cancer. 2016. PMID: 26498503 Review.
BACKGROUND: Thoracic radiotherapy (TRT) has been evaluated as a means of improving overall survival and progression-free survival in patients with extensive stage small-cell lung cancer (ES-SCLC). METHODS: A systematic review of Medline and Emba …
BACKGROUND: Thoracic radiotherapy (TRT) has been evaluated as a means of improving overall survival and progression-free survival in patient …
Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Wang T, Li Y, Zheng X. Wang T, et al. BMC Health Serv Res. 2023 Jun 26;23(1):691. doi: 10.1186/s12913-023-09727-7. BMC Health Serv Res. 2023. PMID: 37365540 Free PMC article.
BACKGROUND: The combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC) was primarily carried out with a combination of immune checkpoint inhibitors (ICIs) and platinum-etoposide (EP). ...
BACKGROUND: The combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer …
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Ohnishi T, Sagara H. Ando K, et al. Curr Oncol. 2021 Feb 27;28(2):1094-1113. doi: 10.3390/curroncol28020106. Curr Oncol. 2021. PMID: 33673470 Free PMC article. Review.
Improving therapeutic strategies for extensive-stage small cell lung cancer (ES-SCLC) remains a challenge. ...
Improving therapeutic strategies for extensive-stage small cell lung cancer (ES-SCLC) remains a challenge …
Preoperative exercise training for people with non-small cell lung cancer.
Granger C, Cavalheri V. Granger C, et al. Cochrane Database Syst Rev. 2022 Sep 28;9(9):CD012020. doi: 10.1002/14651858.CD012020.pub3. Cochrane Database Syst Rev. 2022. PMID: 36170564 Free PMC article. Review.
BACKGROUND: Surgical resection for early-stage non-small cell lung cancer (NSCLC) offers the best chance of cure, but it is associated with a risk of postoperative pulmonary complications. ...It may also reduce postoperative length of hospital stay, an …
BACKGROUND: Surgical resection for early-stage non-small cell lung cancer (NSCLC) offers the best chance of cure …
Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Feng B, Zheng Y, Zhang J, Tang M, Na F. Feng B, et al. Radiother Oncol. 2024 Jan;190:110014. doi: 10.1016/j.radonc.2023.110014. Epub 2023 Nov 18. Radiother Oncol. 2024. PMID: 37981084 Review.
INTRODUCTION: This study aimed to evaluate the efficacy and safety of chemoimmunotherapy combined with consolidative thoracic radiation therapy (cTRT) in patients with extensive-stage small cell lung cancer (ES-SCLC). METHODS: A meta-analysis wa …
INTRODUCTION: This study aimed to evaluate the efficacy and safety of chemoimmunotherapy combined with consolidative thoracic radiation ther …
Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
Korde R, Veluswamy R, Allaire JC, Barnes G. Korde R, et al. Curr Med Res Opin. 2022 Aug;38(8):1361-1368. doi: 10.1080/03007995.2022.2078101. Epub 2022 May 31. Curr Med Res Opin. 2022. PMID: 35575164 Review.
RESULTS: A total of 4961 patients were comprised in all the 12 studies combined. All the studies focus on extensive stage SCLC (ES-SCLC) and not limited stage SCLC (LS-SCLC). ...
RESULTS: A total of 4961 patients were comprised in all the 12 studies combined. All the studies focus on extensive stage SCLC …
The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
Wang BC, Fu C, Lin GH. Wang BC, et al. Front Immunol. 2023 May 5;14:1185577. doi: 10.3389/fimmu.2023.1185577. eCollection 2023. Front Immunol. 2023. PMID: 37215120 Free PMC article.
BACKGROUND: Adebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. ...
BACKGROUND: Adebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell …
Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T, Li W, Diwu D, Chen L, Chen X, Wang H. Zhang T, et al. Front Immunol. 2023 Jun 26;14:1197044. doi: 10.3389/fimmu.2023.1197044. eCollection 2023. Front Immunol. 2023. PMID: 37435087 Free PMC article.
BACKGROUND: Despite numerous immunotherapy and chemotherapy regimens available for patients with extensive-stage small cell lung cancer (ES-SCLC), it remains unclear which regimen is the most effective and safest; relative studies comparing such …
BACKGROUND: Despite numerous immunotherapy and chemotherapy regimens available for patients with extensive-stage small …
47 results